Our business units
We are world leaders in advanced wound management, orthopaedics and sports medicine technologies and solutions.
Overview
We serve our markets through three global business units of Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. These business units are responsible for strategy and global marketing, and contain specialist sales and support teams dedicated to serving the specific requirements of healthcare systems.
We compete in global markets worth around $45 billion per annum.
Advanced Wound Management
The vision of our Advanced Wound Management business unit is to ‘Shape What’s Possible in Wound Care’. Through our extensive portfolio, designed to meet broad and complex clinical needs, we help healthcare professionals solve the challenges of preventing and healing wounds.
In Advanced Wound Care (AWC) our portfolio includes products that are designed to manage exudate and infection, protect the skin and prevent pressure injuries
In Advanced Wound Bioactives (AWB), our products provide a unique approach to debridement, dermal repair, and tissue substitutes.
In Advanced Wound Devices (AWD), our portfolio includes both traditional and single-use Negative Pressure Wound Therapy systems designed to help improve healing outcomes in chronic wounds, prevent surgical site complications and prevent pressure injuries.
Orthopaedics
Our Orthopaedics business unit offers a leading portfolio of hip and knee implants, robotics and digital enabling technologies driving procedural innovation and strengthened Trauma & Extremities portfolio.
Orthopaedics includes an innovative range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that improve accuracy and facilitate precision during the surgical procedure, and trauma products used to stabilise fractures and correct bone deformities.
In Orthopaedic Joint Reconstruction, which includes our Hip and Knee Implants and Other Reconstruction segments, we have a broad, clinically proven and differentiated portfolio. It includes our proprietary OXINIUM◊ Technology and our CORI◊ Surgical System, which is strongly positioned to take advantage of the trends towards robotics-assisted surgery and outpatient joint replacement seen across the segment.
In Trauma & Extremities we offer leading products including plating systems for bone repair, hip fracture systems, external fixator devices and a shoulder replacement and upper and lower extremities portfolio.
Sports Medicine + ENT
Smith+Nephew’s Sports Medicine + ENT business unit leads with innovative procedural solutions to elevate the standard of care in Sports Medicine & ENT.
We operate in growing markets where unmet clinical needs provide opportunities for procedural and technological innovation. We have a rich history of product development, and our technologies, instruments and implants enable surgeons to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip and small joints.
In Sports Medicine Joint Repair (SMJR), we develop products for rotator cuff repair (RCR) and instability repair in the shoulder. In knee repair, our All Tears, All Repairs Meniscal Repair portfolio provides surgeons with unsurpassed options and possibilities for meniscal repair, a novel technology for cartilage regeneration and a comprehensive ligament portfolio. Our hip preservation portfolio contains a broad offering of technologies and techniques, addressing all capsular management needs. We are also committed to redefining healing potential in gluteus medius repairs.
In Arthroscopic Enabling Technologies (AET) our products facilitate arthroscopic surgical procedures, providing a strong foundation of platforms and associated consumables required to perform arthroscopic surgery, including visualisation, fluid management, COBLATION◊ and mechanical resection.
In Ear, Nose & Throat (ENT) we provide low temperature technologies to remove tonsils and adenoids, epistaxis solutions and in-office solution for placement of tympanostomy or ear tubes.
Our marketplace
Smith+Nephew competes in global markets worth around $43 billion, which are driven by long term trends and were growing at approximately 4% annually prior to 2020 and the impact of COVID.
We are the second largest global Advanced Wound Management business in terms of revenue, with the broadest product range.
In the Advanced Wound Care sub-segment we compete with Mölnlycke (Sweden) and ConvaTec (UK). In Advanced Wound Devices, we are the primary challenger to Negative Pressure Wound Therapy incumbent 3M. In our Advanced Wound Bioactives franchise, we have leadership positions in our respective categories.
In our Orthopaedics franchise we are one of four leading players, competing against US-based companies Stryker, Zimmer Biomet and DePuy Synthes.
In Sports Medicine, Smith+Nephew holds a leading position behind Arthrex (US), and also competes against Stryker and DePuy Mitek.